These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30338398)

  • 1. Progress in Inherited Retinal Disease Drug Discovery and Development: A Foundation's Perspective.
    Yerxa B
    Pharm Res; 2018 Oct; 35(11):239. PubMed ID: 30338398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orphan diseases: state of the drug discovery art.
    Volmar CH; Wahlestedt C; Brothers SP
    Wien Med Wochenschr; 2017 Jun; 167(9-10):197-204. PubMed ID: 26819216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Foundation Fighting Blindness Plays an Essential and Expansive Role in Driving Genetic Research for Inherited Retinal Diseases.
    Shaberman B; Durham T
    Genes (Basel); 2019 Jul; 10(7):. PubMed ID: 31284566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma.
    Zhang K; Zhang L; Weinreb RN
    Nat Rev Drug Discov; 2012 Jun; 11(7):541-59. PubMed ID: 22699774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orphan Drugs and Their Impact on Pharmaceutical Development.
    Attwood MM; Rask-Andersen M; Schiöth HB
    Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical assessment programs to evaluate potential therapies for the treatment of orphan retinal diseases.
    Schoen T
    Retina; 2005 Dec; 25(8 Suppl):S64-S65. PubMed ID: 16374343
    [No Abstract]   [Full Text] [Related]  

  • 8. Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases.
    Swinney DC
    Clin Pharmacol Ther; 2016 Oct; 100(4):339-41. PubMed ID: 27393380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a registry and open access genetic testing program for inherited retinal diseases within a non-profit foundation.
    Mansfield BC; Yerxa BR; Branham KH
    Am J Med Genet C Semin Med Genet; 2020 Sep; 184(3):838-845. PubMed ID: 32783387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare lung disease and orphan drug development.
    Spagnolo P; du Bois RM; Cottin V
    Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tackling the Challenges of Product Development Through a Collaborative Rare Disease Network: The Foundation Fighting Blindness Consortium.
    Durham TA; Duncan JL; Ayala AR; Birch DG; Cheetham JK; Ferris FL; Hoyng CB; Pennesi ME; Sahel JA;
    Transl Vis Sci Technol; 2021 Apr; 10(4):23. PubMed ID: 34004001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of academic institutions in the development of drugs for rare and neglected diseases.
    Coles LD; Cloyd JC
    Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rare Diseases: Drug Discovery and Informatics Resource.
    Zhao M; Wei DQ
    Interdiscip Sci; 2018 Mar; 10(1):195-204. PubMed ID: 29094320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular drug discovery in the academic setting: building infrastructure, harnessing strengths, and seeking synergies.
    Gardell SJ; Roth GP; Kelly DP
    J Cardiovasc Transl Res; 2010 Oct; 3(5):431-7. PubMed ID: 20625868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Modern Drug Discovery.
    Eder J; Herrling PL
    Handb Exp Pharmacol; 2016; 232():3-22. PubMed ID: 26330257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye.
    Rodrigues GA; Shalaev E; Karami TK; Cunningham J; Slater NKH; Rivers HM
    Pharm Res; 2018 Dec; 36(2):29. PubMed ID: 30591984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strengthening the Case for Epilepsy Drug Development: Bridging Experiences from the Alzheimer's Disease Field-An Opinion.
    Twyman RE
    Neurochem Res; 2017 Jul; 42(7):2099-2115. PubMed ID: 28589521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Current State of Peptide Drug Discovery: Back to the Future?
    Henninot A; Collins JC; Nuss JM
    J Med Chem; 2018 Feb; 61(4):1382-1414. PubMed ID: 28737935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A generalizable pre-clinical research approach for orphan disease therapy.
    Beaulieu CL; Samuels ME; Ekins S; McMaster CR; Edwards AM; Krainer AR; Hicks GG; Frey BJ; Boycott KM; Mackenzie AE
    Orphanet J Rare Dis; 2012 Jun; 7():39. PubMed ID: 22704758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.
    Bennett J; Wellman J; Marshall KA; McCague S; Ashtari M; DiStefano-Pappas J; Elci OU; Chung DC; Sun J; Wright JF; Cross DR; Aravand P; Cyckowski LL; Bennicelli JL; Mingozzi F; Auricchio A; Pierce EA; Ruggiero J; Leroy BP; Simonelli F; High KA; Maguire AM
    Lancet; 2016 Aug; 388(10045):661-72. PubMed ID: 27375040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.